Feb 16, 2009 - arGentis Pharmaceuticals, LLC announced today that the European Medicines Agency (EMEA) accepted the company's product candidate ARG201 (native type 1 bovine collagen) for the treatment of diffuse systemic sclerosis, also known as systemic scleroderma (SSc) for designation as an orphan medicinal product in the European Union.
The details can be read here.
No comments:
Post a Comment